Prokidney (PROK) Cash from Financing Activities (2021 - 2026)
Prokidney (PROK) reported Cash from Financing Activities of $215000.0 for Q1 2026, up 1891.67% year-over-year from $10795.0 in Q1 2025, and down 98.78% quarter-over-quarter from $17.6 million in Q4 2025.
Prokidney (PROK) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Prokidney (PROK) has 6 years of Cash from Financing Activities data on file, last reported at $215000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $215000.0, up 1891.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.8 million (down 82.14% YoY), and the FY2025 annual result was $25.6 million, down 82.29% from the prior year.
- Cash from Financing Activities slipped to $215000.0 in Q1 2026 per PROK's latest filing, from $17.6 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $507.5 million in Q3 2022 and troughed at -$9.5 million in Q4 2023.
- A 5-year average of $41.7 million and a median of $123000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 18508595.65% in 2022, then plunged 118800.0% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at -$8000.0 in 2022, then sank by 118800.0% to -$9.5 million in 2023, then surged by 101.29% to $123000.0 in 2024, then jumped by 14236.59% to $17.6 million in 2025, then plunged by 98.78% to $215000.0 in 2026.
- Business Quant data shows PROK's Cash from Financing Activities at $215000.0 in Q1 2026, $17.6 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Prokidney | 259.01 Mn | 1.55 Bn | - | 215,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 215,000.00 |
| Mar 31, 2026 | 215,000.00 |
| Dec 31, 2025 | 17.63 Mn |
| Dec 31, 2025 | 17.63 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | -14,000.00 |
| Jun 30, 2025 | -14,000.00 |
| Mar 31, 2025 | -12,000.00 |
| Mar 31, 2025 | -12,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Sep 30, 2024 | 4.46 Mn |
| Sep 30, 2024 | 4.46 Mn |
| Jun 30, 2024 | 139.84 Mn |
| Jun 30, 2024 | 139.84 Mn |
| Mar 31, 2024 | -13,000.00 |
| Mar 31, 2024 | -13,000.00 |
| Dec 31, 2023 | -9.51 Mn |
| Dec 31, 2023 | -9.51 Mn |